DK2164520T3 - Cyclodextriner til indgivelse af fedtsyrer i tabletter - Google Patents

Cyclodextriner til indgivelse af fedtsyrer i tabletter Download PDF

Info

Publication number
DK2164520T3
DK2164520T3 DK08762219T DK08762219T DK2164520T3 DK 2164520 T3 DK2164520 T3 DK 2164520T3 DK 08762219 T DK08762219 T DK 08762219T DK 08762219 T DK08762219 T DK 08762219T DK 2164520 T3 DK2164520 T3 DK 2164520T3
Authority
DK
Denmark
Prior art keywords
cyclodextrins
tablets
administration
fatty acids
fatty
Prior art date
Application number
DK08762219T
Other languages
English (en)
Inventor
Jo Klaveness
Bjarne Brudeli
Pal Rongved
Original Assignee
Golden Omega Norway As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Golden Omega Norway As filed Critical Golden Omega Norway As
Application granted granted Critical
Publication of DK2164520T3 publication Critical patent/DK2164520T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16Cyclodextrin; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/02Cellulose; Modified cellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DK08762219T 2007-05-31 2008-06-02 Cyclodextriner til indgivelse af fedtsyrer i tabletter DK2164520T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0710439.1A GB0710439D0 (en) 2007-05-31 2007-05-31 Oral dosage form
PCT/GB2008/001861 WO2008146016A2 (en) 2007-05-31 2008-06-02 Cyclodextrins for administering fatty acids in tablets

Publications (1)

Publication Number Publication Date
DK2164520T3 true DK2164520T3 (da) 2019-11-25

Family

ID=38289647

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08762219T DK2164520T3 (da) 2007-05-31 2008-06-02 Cyclodextriner til indgivelse af fedtsyrer i tabletter

Country Status (7)

Country Link
US (2) US20100291206A1 (da)
EP (1) EP2164520B1 (da)
DK (1) DK2164520T3 (da)
ES (1) ES2758751T3 (da)
GB (1) GB0710439D0 (da)
PL (1) PL2164520T3 (da)
WO (1) WO2008146016A2 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2049083A2 (en) * 2006-12-27 2009-04-22 Cargill, Incorporated Stabilisation by preparing cyclodextrin inclusion complexes
ITMI20072142A1 (it) * 2007-11-08 2009-05-09 Yervant Zarmanian Composizioni farmaceutiche contenenti statine e derivati di acidi grassi omega-3
GB0817701D0 (en) * 2008-09-26 2008-11-05 Omegatri As Krill oil powder and krill oil tablets
ITFI20080243A1 (it) * 2008-12-15 2010-06-16 Valpharma Sa Formulazioni per la somministrazione orale di acidi grassi omega polienoici in combinazione con statine di origine naturale o semi-sintetica.
US20100272792A1 (en) 2009-04-28 2010-10-28 Avema Pharma Solution, Division of PL Developments Stability additives for dry dha dosage forms
AU2009354456B2 (en) 2009-10-30 2014-05-08 Tharos Ltd Solvent-free process for obtaining phospholipids and neutral enriched krill oils
US20120156296A1 (en) * 2010-12-21 2012-06-21 Omegatri As Antioxidants in fish oil powder and tablets
US20150359807A1 (en) * 2014-06-11 2015-12-17 Supernutrition Life-Extension Research, Inc. Dietary Supplement Containing Vitamin A, D3 and Vitamin K2 and Uses Thereof
US20190364946A1 (en) * 2016-03-16 2019-12-05 Omegatri As Powders and tablets comprising omega-3 fatty acid derivatives and methods for their production
EP3463310B1 (en) * 2016-05-25 2023-07-05 Evonik Operations GmbH Tablets with high active ingredient content of omega-3 fatty acid amino acid salts
CN108057019A (zh) * 2016-11-09 2018-05-22 西宝生物科技(上海)股份有限公司 一种七烯甲萘醌微胶束、其制备方法、含有该微胶束的口服制剂及其应用
CN106511276A (zh) * 2016-12-13 2017-03-22 云南师范大学 水溶性的促凝血药维生素k2固态复合物及其制备方法
CN118715017A (zh) * 2022-02-18 2024-09-27 贝伦治疗公益公司 用2-羟基丙基-β-环糊精治疗高甘油三酯血症

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5813541A (ja) * 1981-07-16 1983-01-26 Kureha Chem Ind Co Ltd エイコサペンタエン酸又はドコサヘキサエン酸のシクロデキストリン包接化合物
GB2140806B (en) * 1983-05-28 1987-10-28 Sekimoto Hiroshi Stabilisation of unsaturated fatty acids, fish oils or fish
JPS6034156A (ja) * 1983-08-08 1985-02-21 Hayashibara Biochem Lab Inc エイコサペンタエン酸包接化合物及びこれを含有した飲食物
US4725427A (en) * 1984-03-13 1988-02-16 Albion International, Inc. Effervescent vitamin-mineral granule preparation
JPS61200942A (ja) * 1985-03-04 1986-09-05 Nisshin Flour Milling Co Ltd ビタミンK↓2−ジメチル−β−シクロデキストリン包接化合物
JPH01218573A (ja) * 1988-02-25 1989-08-31 Yoshio Tanaka ドナリエラ藻体含有固形状食品の製造法
IT1243192B (it) * 1990-08-09 1994-05-24 Staroil Ltd Complessi di acidi grassi polinsaturi a lunga catena e di loro derivati, con ciclodestrine
AU683027B2 (en) * 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
EP0657176B1 (en) * 1993-12-06 2000-09-20 Takeda Chemical Industries, Ltd. Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility
IT1274734B (it) * 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
US5843919A (en) * 1996-11-25 1998-12-01 Burger; John A. Composition and method for the treatment of arthritis
AU719076B2 (en) * 1996-12-19 2000-05-04 Daiichi Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration
KR100267576B1 (ko) * 1998-07-25 2000-11-01 허계성 활성성분을 분리함유한 츄잉 연질정제 및 그의 제조방법
FR2790758A1 (fr) * 1999-03-09 2000-09-15 Commissariat Energie Atomique Solubilisation d'acides gras polyinsatures et de leurs derives par formation de complexes d'inclusion avec une cyclodextrine et leur utilisation dans des compositions pharmaceutiques, cosmetiques ou alimentaires
CN1113657C (zh) * 2000-07-12 2003-07-09 刘玉 高浓鱼油缓释片剂及其制法
GB0212749D0 (en) * 2002-06-01 2002-07-10 Boots Co Plc Personal care compositions
GB0220182D0 (en) * 2002-08-30 2002-10-09 Cardiovascular Res Inst Maastr Organic compounds
JP4689468B2 (ja) * 2003-07-10 2011-05-25 協和発酵バイオ株式会社 錠剤およびその製造方法
EP1858352B1 (en) * 2005-02-18 2013-06-05 Delante Health AS A composition comprising a powder containing microencapsulated polyunsaturated long-chain esterified fatty acids distributed in an effervescent base
JP2006249050A (ja) * 2005-03-14 2006-09-21 Cyclochem:Kk 安定化された複合体及びその製造方法
US20070104779A1 (en) * 2005-11-07 2007-05-10 Rongen Roelof M Treatment with omega-3 fatty acids and products thereof
FR2898817B1 (fr) * 2006-03-23 2008-08-08 Univ Rouen Association de substance oleagineuse avec un melange d'au moins deux cyclodextrines
EP2049083A2 (en) * 2006-12-27 2009-04-22 Cargill, Incorporated Stabilisation by preparing cyclodextrin inclusion complexes

Also Published As

Publication number Publication date
EP2164520A2 (en) 2010-03-24
US20100291206A1 (en) 2010-11-18
GB0710439D0 (en) 2007-07-11
WO2008146016A2 (en) 2008-12-04
WO2008146016A3 (en) 2009-07-16
PL2164520T3 (pl) 2020-04-30
EP2164520B1 (en) 2019-10-30
US20110275594A1 (en) 2011-11-10
ES2758751T3 (es) 2020-05-06

Similar Documents

Publication Publication Date Title
DK2164520T3 (da) Cyclodextriner til indgivelse af fedtsyrer i tabletter
LTPA2018014I1 (lt) Farmacinė kompozicija 514
LTC2140867I2 (lt) Farmacinė kompozicija
DK2345410T3 (da) Farmaceutisk sammensætning til modificeret frigivelse
EP2240022A4 (en) PHARMACEUTICAL COMPOSITIONS
BR112012012108A2 (pt) composição farmacêutica compreendendo propofol
DK2318419T4 (da) Boronatesterforbindelser og farmaceutiske sammensætninger deraf
EP2451274A4 (en) Pharmaceutical compositions
EP2419097A4 (en) PHARMACEUTICAL COMPOSITIONS
EP2373681A4 (en) PHARMACEUTICAL COMPOSITIONS
BRPI0721651A2 (pt) Composição farmacêutica
DK2234994T3 (da) Fedtsyre-butylester-blandinger
DK2273984T3 (da) Lipidsammensætning
DK2328601T3 (da) Linaclotid-holdige formuleringer til oral indgivelse
BRPI0821474A2 (pt) formulação farmacêutica líquida estável
DK2285411T3 (da) Nikotintabletsammensætninger
BRPI0820381A2 (pt) Formulações farmacêuticas
RU2493831C3 (ru) Фармацевтические композиции
DK3159329T3 (da) Anvendelse af 2-hidroxyderivater af polyumættede fedtsyrer som medikamenter
BRPI0921654A2 (pt) formulação farmacêutica
DK2120884T3 (da) Farmaceutisk sammensætning
DK2285413T3 (da) Farmaceutisk sammensætning
DK2391351T3 (da) Farmaceutisk sammensætning omfattende 2-oxo-1-pyrrolidinderivater
EP2236149A4 (en) MEDICAL COMPOSITION
BRPI0921313A2 (pt) composição farmaucêutica